Talisman Metals plc
LLSE:TLM7.75
GBX
-0.75
(-8.82%)
Talisman Metals plc
LSE:TLM
(London Stock Exchange)
Recent
price
7.75
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
EUR
•
in mil. unless spec.Working Capital
EUR
•
in mil. unless spec.Growth Rates
EUR
•
in mil. unless spec.Semi-annual Revenue
EUR
•
in mil. unless spec.Semi-annual Earnings Per Share
EUR
•
in mil. unless spec.Semi-annual Dividends Per Share
EUR
•
in mil. unless spec.- Similar Companies
- Business
- Ovoca Bio plc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel peptide-based therapeutics for women's health, specifically targeting female sexual dysfunction. The company’s core product is Orenetide (BP-101), a novel synthetic peptide administered via nasal spray, designed for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Orenetide works by targeting olfactory and trigeminal nerves to deliver the drug to the brain, addressing a high unmet medical need with limited treatment options. Ovoca Bio also explores additional therapeutic candidates addressing low libido and sexual dysfunction in women. The company operates primarily in Ireland, the United Kingdom, and Russia and holds a broad patent portfolio protecting its technology and product candidates. Founded and incorporated in Ireland, Ovoca Bio leverages a specialized team and partnerships to drive clinical development and commercial planning for Orenetide in major global markets, with a strong focus on the US and European regions. Recent strategic developments include the transition of Orenetide to full ownership by Ovoca Bio after acquiring control of the biotechnology company IVIX in 2018, which originally developed the product. The company has filed for regulatory approvals in the US and Europe and is actively evaluating license and commercialization partnerships to accelerate market access. Ovoca Bio raised significant funding and possesses sufficient cash and liquid assets to support ongoing clinical trials and regulatory submissions. Within the last one to two years, Ovoca Bio faced operational challenges including a clinical study for Orenetide that did not meet statistically significant superiority versus placebo, impacting investor confidence. Despite this setback, the company continues to advance its development program and pursue global market opportunities, including new formulations and treatments. Ovoca Bio’s strategic efforts aim to position it as a leader in developing innovative medicines addressing unmet female health needs, leveraging its clinical-stage pipeline, extensive patent protection, and potential partnership collaborations. The company is listed on the London Stock Exchange under the ticker OVB.L with its headquarters located at 17 Pembroke Street Upper, Dublin, Ireland. Its business segments include biopharmaceutical research and development, investment activities, and administrative functions supporting its female health product portfolios and corporate objectives. Overall, Ovoca Bio remains focused on expanding its product offerings in women's sexual health, commercializing its lead peptide therapeutic Orenetide, and establishing strategic partnerships to broaden its geographic and market reach globally.